PMID- 20347795
OWN - NLM
STAT- MEDLINE
DCOM- 20100617
LR  - 20161125
IS  - 1878-0938 (Electronic)
IS  - 1878-0938 (Linking)
VI  - 11
IP  - 2
DP  - 2010 Apr-Jun
TI  - Intracoronary infusion of CD133+ endothelial progenitor cells improves heart 
      function and quality of life in patients with chronic post-infarct heart 
      insufficiency.
PG  - 72-8
LID - 10.1016/j.carrev.2009.04.001 [doi]
AB  - AIM: To assess the safety and efficacy of the intracoronary infusion of CD133+ 
      hematopoietic stem cells to improve ventricular function and quality of life in 
      candidates for heart transplantation due to post-infarct chronic heart failure. 
      METHODS: We selected seven candidates for heart transplantation (six males/one 
      female, age range 44-65 years) in whom all treatment alternatives were exhausted 
      (angioplasty/stent and bypass surgery). These subjects had a symptomatic New York 
      Heart Association (NYHA) scale of at least II and ejection fractions (EFs) below 
      35%. After obtaining informed consent, CD133+ cells were obtained by stimulation 
      with granulocyte-colony stimulating factor, apheresis, and separation with 
      magnetic beads. Stem cells were implanted in the infarcted zone via intracoronary 
      percutaneous angiography. Evaluations (NYHA scale classification, plasma 
      concentration of pro-B-natriuretic-peptide and the risk of sudden death, 
      echocardiography, cardiac magnetic resonance, and gated-SPECT with MIBI) were 
      performed at baseline and at 3, 6, 12, and 24 months after cell infusion. 
      RESULTS: Stem cell isolation was efficient and safe (around 10(7) cells/patient 
      and >92% CD133+ viable cells). Two patients died during observation due to 
      noncardiac conditions. In the five remaining subjects, the NYHA scale improved 
      and no accounts of hospital admissions for heart failure were documented. Plasma 
      concentrations of pro-B-natriuretic peptide and the risk of sudden death clearly 
      decreased, while the EF increased significantly to 35% and 40% by 
      echocardiography and cardiac MRI, respectively (P=.013 and .009, respectively) 24 
      months after treatment. No other major adverse events were noticed. CONCLUSIONS: 
      The intracoronary inoculation of CD133+ stem cells was safe and effective to 
      improve ventricular contraction and symptomatic class function in patients with 
      refractory post-infarct heart failure.
FAU - Flores-Ramirez, Ramiro
AU  - Flores-Ramirez R
AD  - Hospital y Clinica OCA, S.A. de C.V. Av. Pino Suarez 645 Norte, Colonia Centro, 
      Monterrey C.P. 64000, Mexico.
FAU - Uribe-Longoria, Artemio
AU  - Uribe-Longoria A
FAU - Rangel-Fuentes, Maria M
AU  - Rangel-Fuentes MM
FAU - Gutierrez-Fajardo, Pedro
AU  - Gutierrez-Fajardo P
FAU - Salazar-Riojas, Rosario
AU  - Salazar-Riojas R
FAU - Cervantes-Garcia, Daniel
AU  - Cervantes-Garcia D
FAU - Trevino-Ortiz, Jose H
AU  - Trevino-Ortiz JH
FAU - Benavides-Chereti, Genoveva J
AU  - Benavides-Chereti GJ
FAU - Espinosa-Oliveros, Luciana P
AU  - Espinosa-Oliveros LP
FAU - Limon-Rodriguez, Ramon H
AU  - Limon-Rodriguez RH
FAU - Monreal-Puente, Rogelio
AU  - Monreal-Puente R
FAU - Gonzalez-Trevino, Juan L
AU  - Gonzalez-Trevino JL
FAU - Rojas-Martinez, Augusto
AU  - Rojas-Martinez A
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Cardiovasc Revasc Med
JT  - Cardiovascular revascularization medicine : including molecular interventions
JID - 101238551
RN  - 0 (AC133 Antigen)
RN  - 0 (Antigens, CD)
RN  - 0 (Biomarkers)
RN  - 0 (Glycoproteins)
RN  - 0 (PROM1 protein, human)
RN  - 0 (Peptides)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
SB  - IM
MH  - AC133 Antigen
MH  - Adult
MH  - Aged
MH  - Antigens, CD/*analysis
MH  - Biomarkers/blood
MH  - Cell Separation
MH  - Chronic Disease
MH  - Coronary Angiography
MH  - Death, Sudden, Cardiac/etiology/prevention & control
MH  - Echocardiography
MH  - Endothelial Cells/immunology/*transplantation
MH  - Female
MH  - Glycoproteins/*analysis
MH  - Heart Failure/diagnosis/etiology/physiopathology/psychology/*therapy
MH  - *Hematopoietic Stem Cell Transplantation/adverse effects
MH  - Humans
MH  - Infusions, Intra-Arterial
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Myocardial Contraction
MH  - Myocardial Infarction/*complications/diagnosis/physiopathology/psychology
MH  - Natriuretic Peptide, Brain/blood
MH  - Peptides/*analysis
MH  - *Quality of Life
MH  - Recovery of Function
MH  - Stroke Volume
MH  - Time Factors
MH  - Tomography, Emission-Computed, Single-Photon
MH  - Treatment Outcome
MH  - *Ventricular Function, Left
EDAT- 2010/03/30 06:00
MHDA- 2010/06/18 06:00
CRDT- 2010/03/30 06:00
PHST- 2009/01/20 00:00 [received]
PHST- 2009/03/27 00:00 [revised]
PHST- 2009/04/02 00:00 [accepted]
PHST- 2010/03/30 06:00 [entrez]
PHST- 2010/03/30 06:00 [pubmed]
PHST- 2010/06/18 06:00 [medline]
AID - S1553-8389(09)00089-X [pii]
AID - 10.1016/j.carrev.2009.04.001 [doi]
PST - ppublish
SO  - Cardiovasc Revasc Med. 2010 Apr-Jun;11(2):72-8. doi: 
      10.1016/j.carrev.2009.04.001.